Biohaven Pharmaceutical Holding Company Ltd. (BHVN) financial statements (2020 and earlier)

Company profile

Business Address 215 CHURCH STREET
NEW HAVEN, CT 06510
State of Incorp.
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

9/30/2019
TTM
12/31/2018
12/31/2017
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments417264131
Cash and cash equivalents417264131
Prepaid expense675
Other current assets100
Other undisclosed current assets 00
Total current assets:423272137
Noncurrent Assets
Property, plant and equipment762
Long-term investments and receivables7118
Long-term investments7118
Other undisclosed noncurrent assets100
Total noncurrent assets:161810
TOTAL ASSETS:439290147
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities47209
Accounts payable12115
Accrued liabilities3695
Total current liabilities:47209
Noncurrent Liabilities
Liabilities, other than long-term debt13621
Financial instruments subject to mandatory redemption, settlement terms, share value, amount99  
Other liabilities021
Derivative instruments and hedges, liabilities37  
Other undisclosed noncurrent liabilities1371184
Total noncurrent liabilities:2731205
Total liabilities:32013915
Stockholders' equity
Stockholders' equity attributable to parent119151132
Common stock875554311
Additional paid in capital674024
Accumulated deficit(823)(444)(203)
Total stockholders' equity:119151132
TOTAL LIABILITIES AND EQUITY:439290147

Income statement (P&L) ($ in millions)

9/30/2019
TTM
12/31/2018
12/31/2017
Operating expenses(392)(225)(108)
Operating loss:(392)(225)(108)
Nonoperating expense(41)(16)(19)
Other nonoperating expense(0)(0)(19)
Interest and debt expense(8)(0)(1)
Other undisclosed income from continuing operations before equity method investments, income taxes801
Loss from continuing operations before income taxes:(434)(240)(126)
Income tax expense(1)(0)(1)
Net loss attributable to parent:(434)(241)(127)
Other undisclosed net loss available to common stockholders, basic  (12)
Net loss available to common stockholders, diluted:(434)(241)(139)

Comprehensive Income ($ in millions)

9/30/2019
TTM
12/31/2018
12/31/2017
Net loss:(434)(241)(127)
Comprehensive loss, net of tax, attributable to parent:(434)(241)(127)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: